Participated · Equity · Oct 2022

Gabbi is a Portland, OR-based risk assessment and care navigation company focused on early breast cancer detection. Its solution delivers immediate, accurate risk assessment results, personalized ongoing care plans, and a care concierge for women of all ages and ethnicities. Led by founder and CEO Kaitlin Christine, Gabbi aims to help users detect breast cancer at the earliest treatable stages. The company raised $4.4M in funding and will use the proceeds for team growth and product development. Gabbi plans to launch at the beginning of 2023 via employers who will provide Gabbi as a benefit to their employees.

Led · Series A · Sep 2022

Proov (MFB Fertility, Inc.) develops at-home hormone tests and created the first and only FDA-cleared PdG-testing kit to confirm ovulation quality. Its patented PdG protocol and the Proov Insight app provide quantitative hormone results, end-of-cycle reports, and stored hormone trends without an external reader. The company expanded its product lineup to include Proov Predict & Confirm and has launched Proov Complete, an at-home suite that measures FSH, LH, E1G (estrogen marker) and PdG. Proov says the Complete product and app deliver a comprehensive and affordable at-home hormonal pattern analysis across the menstrual cycle. The company was originally co-founded in Boulder, Colo. by two women who struggled to conceive and is led by CEO Amy Beckley. Proov raised a Series A to support the Complete product and to expand accessibility and physician partnerships. Proov is an at-home fertility diagnostics company launched by MFB Fertility Inc. in 2018 and co-founded in Boulder, Colorado by two women who struggled to conceive. Its FDA-approved test measures the progesterone metabolite PdG in urine to help women confirm ovulation; low progesterone is cited as a leading cause of infertility and preventable miscarriage. Demand for at-home testing kits has surged amid Covid-19, driving the company to scale production and accelerate research and development. The company recently received undisclosed funding from Lightship Capital and the Texas HALO Fund, plus additional angel investors, to support growth and new product launches. Proov also holds a $1.3 million contract with the U.S. Air Force to provide free kits and connect military couples with fertility specialists. CEO Amy Beckley said the investment will help Proov expand its product offering and continue developing fertility tools to deliver more accessible reproductive-health solutions.

Participated · Series C · Nov 2020

Buoy Health is a Boston, MA-based AI-powered healthcare navigation platform that provides personalized clinical support the moment an individual has a health concern. Developed out of the Harvard Innovation Labs by a team of doctors and data scientists, the company navigates people through the healthcare system, delivering triage at scale. It connects users with the right care endpoints at the right time based on self-reported symptoms. Led by Andrew Le, MD, CEO and co-founder, Buoy uses AI technology to power its clinical support. The company raised $37.5M in Series C funding, bringing total capital raised to $66.5M to date. Buoy intends to use the funds to further build out its AI-related intellectual property and other technologies, and to grow the team. Buoy Health is a Boston, MA-based health platform powered by an advanced artificial intelligence engine to provide personalized clinical support to individuals. The company uses a symptom self-assessment to generate real-time, high-quality care recommendations (virtual, in-person, or emergency) and follows up via an omni-channel approach tied to symptom severity to help close gaps in care. Its technology delivers intelligent care recommendations and care-pathway guidance after a user assessment. Buoy is led by Dr. Andrew Le, CEO and co-founder. Financially, Buoy has been funding its growth through a Series B: it announced a $15m component in August 2019 and received an additional approximately $5m from Cigna Ventures in January 2020, bringing the Series B total to roughly $20m. Investors participating in the Series B include Hambrecht Ducera Growth Ventures, Humana, F-Prime Capital Partners, Optum Ventures and Cigna Ventures. Buoy Health operates an all-in-one platform powered by an advanced AI engine to deliver personalized clinical support and digital triage for people with health concerns. The tool acts as a front-door to care, guiding users through complex information and helping them navigate the healthcare system. Buoy’s digital triage has been shown to de-escalate the intent for nearly 40% of emergency-room visits. The company reports roughly 6.7 million annual interactions and 3.7 million completed self-triage interviews each year. Buoy was developed out of the Harvard Innovation Labs by a team of doctors and data scientists. The company plans to continue rapid U.S. growth and expand its enterprise offering to new populations, including Baby Boomers and Medicaid-covered patients. Buoy is a health startup that uses an intelligent algorithm backed by medical data to guess what ails users. The company debuted in March to compete with WebMD and other online symptom checkers and says its algorithm can more accurately diagnose patients. Founder Andrew Le, a Harvard-trained MD, said Buoy implemented a battery of tests and conducted a series of studies to ensure accuracy. Buoy reports rapid growth, with more than a quarter of a million people having used the platform. The $6.7M Series A will be used to recruit additional clinical researchers, engineers, and marketers and to build integrations with hospitals and providers. FundRx will also supply physicians for a new medical board to support the product and clinical oversight.

Participated · Series C · Nov 2015

ElMindA develops the Brain Network Activation (BNA™) system, a non-invasive multi-channel EEG-ERP platform that applies advanced signal processing and machine-learning to map neuronal networks during specific brain functions. The technology is positioned to support clinical decision making for conditions such as concussion, Alzheimer’s, Parkinson’s, depression, ADHD and other brain disorders. BNA received FDA clearance in 2014 for a specific indication and holds a CE Mark in Europe. The company plans to use new funding to continue technical advancement of BNA and to drive commercial and clinical adoption. BNA is already available to healthcare providers at 15 locations across eight U.S. cities. ElMindA was founded in 2006 and is headquartered in Chicago.